Anti nausea treatment based on individual genetic alterations (SNP) and simultaneous test of the validity of acupressure in conjuction with chemotherapy in women with breast cancer.
- Conditions
- ausea in conjuction with neoadjuvant or adjuvant chemotherapy (FEC/EC) for patients with breast cancer.Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2015-000658-39-SE
- Lead Sponsor
- Region Jönköpings län
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 840
Until 31 Dec 2020: Women with verified breast cancer planed for first neoadjuvant or adjuvant FEC/EC chemotherapy an
Age = 18 years
From 2021:
Patients with a cancer diagnosis that are planned for potentially emetogenic chemotherapy
Knowledge of the Swedish language
Informed consent in writing
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 590
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 250
? Distant metastases in patients treated in an adjuvant setting
? Previous treatment with chemotherapy
? Unable to understand information about the study
Only until 31 Dec 2020: Contra indication against betamethasone
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method